New wire may cut X-Ray risk during heart ablation

NCT ID NCT07515040

Recruiting now Symptom relief Sponsor: Second Affiliated Hospital of Nanchang University Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compares a new guidewire (AccuSafe) to the standard needle used to cross the heart wall during catheter ablation for atrial fibrillation. The goal is to see if the guidewire is safer and more effective, especially when done without X-ray guidance. 80 patients will be randomly assigned to one of the two devices, and researchers will track success rates, procedure time, and complications.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AccuSafe transseptal guidewire
What this could lead to: If successful, this guidewire could make a key step in AF ablation safer, faster, and radiation-free for patients and doctors.
What could go wrong: This is a small, early-stage study (80 patients) comparing a device to standard care. Results may not apply to all patients or settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATRIAL FIBRILLATION (AF) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atrial fibrillation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATRIAL FIBRILLATION (AF)

Contacts and locations

Locations

The Second Affiliated Hospital of Nanchang University
RECRUITING

Nanchang, Jiangxi, 330006, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.